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Study population
Dyslipidemia was defined as a fasting low-density lipoprotein cholesterol of 140 mg/dL or more, high-density lipoprotein cholesterol of less than 40 mg/dL, triglycerides level of 150 mg/dL or more, or the use of lipid lowering drugs. Hypertension was defined as a clinic systolic blood pressure of 140 mm Hg or more, diastolic blood pressure of 90 mm Hg or more, or the use of anti-hypertensive drugs. Diabetes was defined as a fasting glucose of 126 mg/dL or more, glycosylated hemoglobin of 6.5% or more, or the use of oral hypoglycemic drugs or insulin. The presence of coronary artery disease (CAD), multi-vessel disease, and left main trunk disease was assessed using a modified American Heart Association/American College of Cardiology classification. 1 The severity of CAD was quantified using the Gensini score. 2 
Sample collection and biomarker measurement
The secondary predictors were vascular endothelial growth factor (VEGF), soluble vascular VEGF receptor-2 (sVEGFR-2) and two oxidatively modified low-density lipoproteins (LDLs), i.e. the α1-antitrypsin/LDL complex (AT-LDL) and serum-amyloid-A/LDL complex (SAA-LDL).
Fasting blood samples for serum were collected from the arterial catheter sheath at the beginning of coronary angiography. Serum (200 μL) was treated at 4°C for the measurements of AT-LDL and SAA-LDL, with the use of specific sandwich enzyme-linked immunosorbent assays (ELISA) (Ikagaku [now Health Sciences Research Institute West Japan], Kyoto, Japan). 3, 4 The remaining serum was stored at -80°C for a mean of 2 years until being assayed for other biomarkers. The serum levels of VEGF, sVEGFR-2, and highsensitivity C-reactive protein (hs-CRP) were measured with specific, commercially available ELISA kits according to the manufacturers' instructions (Quantikine, R&D Systems, Minneapolis, MN, for VEGF, and sVEGFR-2; CycLex, MBL, Nagano, Japan for hs-CRP). 5 The sensitivities of the assays for VEGF, sVEGFR-2, and hs-CRP were 5.0, 4.6, and 28.6 pg/ml, respectively. The inter-/intra-assay coefficients of variation (CV) of ELISA for VEGF, sVEGFR-2, and hs-CRP were <9%/<7%, ≤7%/<5%, and <6%/<4%, respectively. The sensitivity of the assay for N-terminal pro-brain natriuretic peptide (NT-proBNP) was 5 pg/mL, and the assay CV at values of the measuring range (5-35,000 pg/mL) was <10%.
The sensitivity of the assay for contemporary sensitive cardiac troponin-I (cTnI) was 6 pg/mL, and the assay CV at the 99th percentile reference value of 40 pg/mL (potential range, 20-60 pg/mL) was <10%. The hemoglobin and the hematocrit levels, plasma hemoglobin A1c levels, and fasting serum levels of low-density lipoprotein cholesterol, highdensity lipoprotein cholesterol, triglycerides, glucose, creatinine, and uric acid were measured by routine methods.
Statistical analyses
The baseline clinical characteristics and outcome data are presented as means and standard deviations, medians and interquartile range, or number and proportions, as appropriate. The relationships between the baseline biomarker levels and the outcomes were investigated with the use of Cox proportional hazard regression in three sets of models:
age-and sex-adjusted models; models adjusted for age, sex, traditional risk factors (dyslipidemia, hypertension, diabetes, and current smoking), obesity (defined as a body mass index of 25 kg/m 2 or more), chronic kidney disease (CKD) (defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m 2 ), a history of cardiovascular events (myocardial infarction, stroke, heart failure hospitalization, and coronary revascularization), CAD, multi-vessel or left main trunk disease, statin use, aspirin use, and anti-hypertensive drug use; models adjusted for established risk factors (age, sex, traditional risk factors, obesity, CKD, a history of cardiovascular events, CAD, multi-vessel or left main trunk disease, statin use, aspirin use, and anti-hypertensive drug use), and high levels of NTproBNP, cTnI, and hs-CRP (for values above the cutoff points determined as previously reported). [6] [7] [8] The necessary number of patients to treat in the present study was estimated on the basis of the association between the sVEGFR-2 level and cardiovascular events in a preliminary cohort study. In that study, a total of 513 patients were followed up over 3 years, and a total of 67 (13%) developed initial cardiovascular events. When the patients were divided into two groups using the optimal cut-off value determined by a receiver operating curve analysis, the event rates were 15.5% and 8.2%, respectively. Therefore, for 99% power and an alpha risk of 1% in the log-rank test for the Kaplan-Meier method, the minimum sample size was calculated as 955 and 1,039 in each group (1,994 in total). We estimated that the data of approximately 20% patients would be incomplete, and thus the target number of patients was 2,500. VEGF-C, vascular endothelial growth factor-C; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; IQR, interquartile range; SD, standard deviation; LDL, low-density lipoprotein;
HDL, high-density lipoprotein; GFR, glomerular filtration rate; VEGF, vascular endothelial growth factor; sVEGFR-2, soluble vascular endothelial growth factor receptor-2; SAA-LDL, serum-amyloid-A/low-density-lipoprotein complex; AT-LDL, α1-antitrypsin/low-density-lipoprotein complex;
RASI, renin angiotensin system inhibitors; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; MACE, major adverse cardiovascular event.
Values are expressed as number (percentage) unless otherwise indicated. . §The Gensini score represents the angiographic severity of coronary artery disease employing a nonlinear points system for degree of luminal narrowing.
|| The MACE is defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. natriuretic peptide (>75th percentile), contemporary sensitive cardiac troponin I (>75th percentile), and high-sensitivity C-reactive protein (>1.0 g/mL).
